Epidemiology of Psoriasis in Portugal: A Population-Based Study

Torres, Tiago; Filipe, Paulo; Brandão, Francisco Menezes; Figueiredo, Américo; Soares, António Ferreira; Basto, Artur Sousa; Rebelo, Clarisse; Correia, Osvaldo; Ferreira, Paulo; Brasileiro, Ana; Mendes‐Bastos, Pedro; Paiva-Lopes, Maria João; Pinto, Gabriela Marques; Severo, Milton; Mendonça, Denisa; Oliveira, Pedro F.; Selores, Manuela; Massa, António; Pereira, Magnum de Sousa; Bello, Rui Tavares

doi:10.20344/amp.19048

Cited by 4 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study found a slightly higher decrease in ASPR and ASIR in females between 2019 and 1990, while similar changes in ASDR were observed between both genders. Most studies found in the literature reported higher rates of prevalence and incidence in males than females [28][29][30][31][32][33][34], while other studies reported no differences between males and females [24,[35][36][37], and some described that females had higher incidence and prevalence [35,38,39]. The disparities in reported rates between males and females in various studies may be due to varying risk factors distributions between both groups [40], as well as the underrepresentation of female cases as mentioned previously, particularly in countries with lower SDI levels.…”

Section: Rates Differences By Gender and Agementioning

confidence: 99%

The Burden of Psoriasis Across United States: Findings From the 2019 Global Burden of Diseases Study and Forecasts From 2025 to 2035

Al-omoush,

HajAli,

Assaf

et al. 2024

CAJMHE

View full text Add to dashboard Cite

Background. Psoriasis is a concerned public health problem across the world. Previous studies have often concentrated on the disease burden globally and in MENA areas. However, the epidemiological patterns and burden of psoriasis in the US are still lacking. This study aims to assess the incidence, prevalence, and DALYs of RA in the US between 1990 and 2019, with a pattern prediction for the next ten years addressing the lack of comprehensive research on the disease's epidemiological patterns. Moreover, correlations between incidence, prevalence, DALYs, and SDI will be examined. Methods. The incidence, prevalence, and DALYs in the US were investigated by age, gender, SDI, and state using the data from Global burden disease (GBD). All estimates were generated using age-standardized rates per 100,000 individuals and rate change, with 95% Uncertainty Intervals (UIs). Pearson correlation was used to analyze the relationships between incidence, prevalence, DALYs, and SDI. The forecast analysis was performed using R software, utilizing some of its packages. Results. The US experienced a decrease in psoriasis prevalence and incidence since 1990, with females experiencing a slightly higher decrease than men. However, US DALY rates have decreased, with males and females experiencing similar decreases. New York and Massachusetts had the highest rates, while Wyoming had the lowest. A significant positive correlation (modest power) was found between SDI and incidence, prevalence, and DALYs. The forecasting period (2025-2035) indicates that psoriasis incidence remains steady among young people of both ages, with a minor increase in elderly people. In terms of DALYs, both age groups expected a progressive decline in psoriasis. Conclusion. Psoriasis is still a major cause of health burden in the US with considerable differences extending between states. Updating accessible health data is required to provide more precise guidelines for the early identification and treatment of psoriasis.

show abstract

Section: Rates Differences By Gender and Agementioning

confidence: 99%

The Burden of Psoriasis Across United States: Findings From the 2019 Global Burden of Diseases Study and Forecasts From 2025 to 2035

Al-omoush,

HajAli,

Assaf

et al. 2024

CAJMHE

View full text Add to dashboard Cite

show abstract

“…Psoriasis is an immune-mediated skin disease that is estimated to affect 4.4% of the Portuguese population. 1 It can manifest at any age and imposes a significant burden on the patients due to its chronic nature, disfigurement, disability and associated comorbidities. 2,3 Major advances in immunological and genetic studies have identified IL-17 and IL-23 as key drivers in psoriatic inflammation.…”

Section: Introductionmentioning

confidence: 99%

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study

Torres,

Varela,

Mendes Bastos

et al. 2024

DIC

View full text Add to dashboard Cite

Background Real-world evidence plays a pivotal role in validating the efficacy of biologic drugs beyond the controlled environment of randomized trials. This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in Portugal. Methods This multicentric, prospective, observational study included adult patients with moderate-to-severe psoriasis. All participants received tildrakizumab 100 mg at weeks 0 and 4, followed by a maintenance dose every 12 weeks, and were monitored for 52 weeks. Primary endpoints were determined based on Psoriasis Area and Severity Index (PASI) assessments at baseline, 16 (±2) weeks, 28 (±2) weeks and 52 (±2) weeks. Results A total of 54 patients were enrolled in the study (56% men, mean age of 50.3 ± 14.4 years). Half of the sample ( n =27) had no prior experience with biologic treatments. About 74% of patients ( n =40) presented at least one comorbidity during the study, with psoriatic arthritis being the most prevalent (29.6%). By week 52, there was a significant decrease in the mean PASI from 17.8±10.3 at baseline to 1.3±1.9 ( p <0.001), indicating an overall improvement of 93%. By week 52, more than 85% of patients attained PASI ≤5, more than 80% reached PASI ≤3, and nearly 60% achieved PASI ≤1. Infections were observed in 9.3% of patients, and one patient required hospitalization (1.9%). The cumulative proportion of patients continuing treatment at 52 weeks was 88.9%. Conclusions This study demonstrates that tildrakizumab is an effective and safe agent for the treatment of moderate-to-severe psoriasis in a diverse, real-world setting.

show abstract

“…1,2 It is estimated that approximately 400 000 people live with psoriasis in Portugal. 3 We discuss the case of a 54-year-old man with inconsistent follow-up for psoriasis for 15 years and who also had, depression and alcohol dependence with psychiatry followup, and was referred to social services due to financial issues causing poor therapy adherence. The patient presented to the emergency department with erythematous, scaly plaques sparing only the cervical and facial regions, with a high Psoriasis Area and Severity Index (PASI) of 65 (range 0-72) (Fig.…”

mentioning

confidence: 99%